 |
 |
|
|
Articles 
Alan S. Go, Carlos Iribarren, Malini Chandra, Phenius V. Lathon, Stephen P. Fortmann, Thomas Quertermous, Mark A. Hlatky for the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study This case–control study of 1384 adults from a large prepaid group practice evaluated the effect of current use of statins or ß-blockers at first presentation of coronary heart disease. Use of these drugs was associated with lower odds of presenting with an acute myocardial infarction and higher odds of presenting with stable angina. Additional studies are needed to prove that these therapies protect against unstable, higher-risk clinical presentations of coronary disease.
Bronwyn A.L. Crawford, Cherie Kam, Julie Pavlovic, Karen Byth, David J. Handelsman, Peter W. Angus, and Geoffrey W. McCaughan Clinically important rapid bone loss occurs within 3 to 6 months after liver transplantation and may be associated with osteoporotic fractures. In this clinical trial, bone mineral density decreased during the postoperative period in patients taking placebo but did not change in patients taking zoledronic acid.
Mary J. Roman, Elfi Moeller, Adrienne Davis, Stephen A. Paget, Mary K. Crow, Michael D. Lockshin, Lisa Sammaritano, Richard B. Devereux, Joseph E. Schwartz, Daniel M. Levine, and Jane E. Salmon Rheumatoid arthritis is associated with increased morbidity and mortality due to cardiovascular disease. In this matched, cross-sectional study, patients with rheumatoid arthritis had a somewhat more favorable cardiovascular risk profile than the controls. Nonetheless, patients with rheumatoid arthritis had a much higher prevalence of preclinical atherosclerosis of the carotid artery than did the matched controls.
Stephen Bent, Amy Padula, and Andrew L. Avins In an existing clinical trial, 214 men were divided into 3 groups to measure the effect of 3 methods to assess adverse events: an open-ended question; an open-ended, defined question; and a checklist of 53 common side effects. The checklist group was much more likely to report an adverse event (14%, 13%, and 77%, respectively). Researchers should use the same method to assess adverse events in clinical trials.
Improving Patient Care
Peter K. Lindenauer, Raj Behal, Cynthia K. Murray, Wato Nsa, Peter M. Houck, and Dale W. Bratzler In this study of the annual pneumonia caseload of physicians and hospitals, the number of cases was not a powerful determinant of quality of care or outcome. Higher volume was associated with lower adherence to guideline recommendations. The best targets for quality improvement efforts were the timeliness of antibiotic administration, especially at high-volume institutions, and hospital-based vaccination rates.
Updates
Paul L. Kimmel This Update includes papers that presented a new way of classifying chronic kidney disease, established a new association between chronic kidney disease and the metabolic syndrome, and compared the equations that are used to define chronic kidney disease. The Update also discusses noteworthy research on the prevention and treatment of diabetic nephropathy, hyperkalemia, and the prevention of contract agent–induced nephropathy.
Reviews
Jon-Erik C. Holty, Dena M. Bravata, Hau Liu, Richard A. Olshen, Kathryn M. McDonald, and Douglas K. Owens Despite advances in supportive care, fulminant-phase inhalational anthrax is usually fatal. Initiation of antibiotic or anthrax antiserum therapy during the prodromal phase is associated with markedly improved survival, although other aspects of care, differences in clinical circumstances, or unreported factors may also have some effect. Earlier diagnosis and faster initiation of appropriate antibiotics are critical to decreasing mortality rates.
History of Medicine
Bernhard Glodny and Dorothea E. Glodny In 1934, Harry Goldblatt and colleagues published a landmark article: "The Production of Persistent Elevation of Systolic Blood Pressure by Means of Renal Ischemia." One year earlier, John Loesch had published a similar study in a German-language journal. The central proposition of both papers was the same: Renal ischemia causes persistent hypertension. Although Loesch was the first to produce persistent hypertension by inducing ischemia, his work is essentially unknown. Loesch and Goldblatt deserve equal credit for these important first observations.
Editorials
Sidney C. Smith, Jr In this issue, Go and colleagues suggest that the use of statin and ß-blocker therapy might favorably alter the initial clinical presentation of coronary heart disease. We need to perform randomized clinical trials to confirm these findings in appropriate patient groups and investigate their mechanisms. If confirmed by such trials, these findings could have a substantial effect on patient care.
John P.A. Ioannidis, Cynthia D. Mulrow, and Steven N. Goodman Physicians rely on compendia and product inserts to learn about medication-related harms. These materials offer litanies of possible adverse events, sometimes accompanied by an estimate of how often those events might occur. From whence are the estimates derived? What do they really mean? How can we better measure and understand how many and what kinds of harms may be caused by medications? In this issue, Bent and colleagues remind us that how we define and look for problems markedly affects the numbers of harms that patients report.
On Being a Doctor
Jon O. Neher I was driving home late one night when suddenly a dozen red taillights flashed in front of me. I hit my brakes. In my peripheral vision, I caught sight of a pile of clothing lying in the center lane. At first I thought that it was just some garbage that had come off the back of a truck. But as I rolled slowly past, I developed a sickening feeling. The clothing was not arranged randomly. It was held together in some dimly recognizable order.
Letters Amiodarone Prophylaxis
Genetic Risk Assessment and BRCA Mutation Testing
The Ethics of Personal Stockpiles
Relevance of Patient Diagnosis to Analysis of the Terri Schiavo Case
Relevance of Patient Diagnosis to Analysis of Terri Schiavo Case
Setting the Agenda for the Clinical Interview
Reporting of Drug Tolerance in Randomized Clinical Trials: When Data Conflict with Authors' Conclusions
Correction: Summary for Patients: Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility
Jack Coulehan
| |||||||||||||||||||||||||||||||||||||||||||
In this Issue
Articles
Previous Issue